keyword
MENU ▼
Read by QxMD icon Read
search

Her-2

keyword
https://www.readbyqxmd.com/read/29344265/high-expression-of-pu-1-is-associated-with-her-2-and-shorter-survival-in-patients-with-breast-cancer
#1
Jing Lin, Wei Liu, Tian Luan, Lili Yuan, Wei Jiang, Huilong Cai, Weiguang Yuan, Yuwen Wang, Qingyuan Zhang, Lihong Wang
The transcription factor PU.1 was previously identified as an oncogene or a tumor suppressor in different types of leukemia. The aim of the present study was to investigate the expression of PU.1 in breast cancer and to analyze its association with clinical features and prognosis. Immunohistochemistry was used to determine PU.1 expression in breast cancer tissue microarrays and paraffin-embedded sections. The association between PU.1 expression and clinicopathological factors was assessed by using chi-square test...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344258/involvement-of-breast-cancer-stem-cells-in-tumor-angiogenesis
#2
Yu Wang, Chen Li, Yuqiang Li, Zhitu Zhu
The aim of the present study was to investigate the role of breast cancer stem cells (BCSCs) in the angiogenesis of breast cancer tumors. The expression levels of mutant p53, cluster of differentiation (CD)31, vascular endothelial factor (VEGF), in addition to human epidermal growth factor (HER)2, were detected in the blood vessels of human breast cancer (BC) tissue samples. CD44+/CD24-/low cells were selected from single-cell suspensions of BC tissues to assess the expression of CD31 and CD105, in addition to the ability of these cells to metabolize acetylated low-density lipoprotein (Ac-LDL)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29333017/correlation-of-hormone-receptor-and-human-epidermal-growth-factor-receptor-2-neu-expression-in-breast-cancer-with-various-clinicopathologic-factors
#3
Cherry Bansal, Aarti Sharma, Mukta Pujani, Meenu Pujani, Kiran Lata Sharma, A N Srivastava, U S Singh
Background: A significant development in the breast carcinoma management is the correlation between the presence of hormone receptors in the tumor and response to hormonal therapy and chemotherapy. Human epidermal growth factor receptor-2/neu (Her-2/neu) overexpression also serves as a very useful parameter to predict response to herceptin. Aim of Study: The study was conducted to correlate immunohistochemical expression of markers such as estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu with various clinicopathologic parameters...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29331430/disposable-inkjet-printed-electrochemical-platform-for-detection-of-clinically-relevant-her-2-breast-cancer-biomarker
#4
Susanita Carvajal, Samantha N Fera, Abby L Jones, Thaisa A Baldo, Islam M Mosa, James F Rusling, Colleen E Krause
Rapidly fabricated, disposable sensor platforms hold tremendous promise for point-of-care detection. Here, we present an inexpensive (< $0.25) fully inkjet printed electrochemical sensor with integrated counter, reference, and working electrodes that is easily scalable for commercial fabrication. The electrochemical sensor platform featured an inkjet printed gold working 8-electrode array (WEA) and counter electrode (CE), along with an inkjet -printed silver electrode that was chlorinated with bleach to produce a Ag/AgCl quasi-reference electrode (RE)...
January 4, 2018: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/29326440/braf-inhibition-upregulates-a-variety-of-receptor-tyrosine-kinases-and-their-downstream-effector-gab2-in-colorectal-cancer-cell-lines
#5
Ricarda Herr, Sebastian Halbach, Miriam Heizmann, Hauke Busch, Melanie Boerries, Tilman Brummer
BRAF mutations occur in ~10% of colorectal cancer (CRC) and are associated with poor prognosis. Inhibitors selective for the BRAFV600E oncoprotein, the most common BRAF mutant, elicit only poor response rates in BRAF-mutant CRC as single agents. This unresponsiveness was mechanistically attributed to the loss of negative feedbacks on the epidermal growth factor receptor (EGFR) and initiated clinical trials that combine BRAF (and MEK) inhibitors, either singly or in combination, with the anti-EGFR antibodies cetuximab or panitumumab...
January 12, 2018: Oncogene
https://www.readbyqxmd.com/read/29321957/high-expression-of-palb2-predicts-poor-prognosis-in-patients-with-advanced-breast-cancer
#6
Jingquan Li, Mian Li, Peizhan Chen, Qian Ba
PALB2 mutation is associated with increased breast cancer risk; however, PALB2 mutation is rare in sporadic breast cancer cases and little is known about PALB2 expression in breast cancer. Here, we evaluated the prognostic effects of PALB2 with tissue microarray specimens of 117 female breast cancer patients, and determined the potential underlying mechanisms in cell models. In immunohistochemical analysis, we found increased expression of PALB2 in breast cancer tissues compared with the adjacent normal ductal epithelium (P < 0...
January 2018: FEBS Open Bio
https://www.readbyqxmd.com/read/29320969/differential-expression-of-tgf%C3%AE-isoforms-in-breast-cancer-highlights-different-roles-during-breast-cancer-progression
#7
Mahmood Y Hachim, Ibrahim Y Hachim, Meiou Dai, Suhad Ali, Jean-Jacques Lebrun
While TGFβ plays a critical role in tumor formation and progression, the role and contribution of its three different isoforms remain unclear. In this study, we aimed at elucidating the prognostic value of the TGFβ isoforms and assessed their expression levels in breast cancer patients at different stages of the disease. We found higher levels of TGFβ1 and TGFβ3 in cancer patients compared to normal tissues, with no significant changes in TGFβ2 expression. Similarly, TGFβ1 and TGFβ3, but not TGFβ2, showed higher expression levels in advanced lymph node-positive and metastatic tumors, suggesting different roles for the different isoforms in tumor progression and the metastatic process, while in the least aggressive molecular subtype (luminal A), expression of the three TGFβ isoforms significantly correlated with expression of both TGFβ receptors, such correlation only occurred between TGFβ1 and TGFβ3 and the TGFβ type II receptor (TβRII) in the highly aggressive basal-like subtype...
January 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29320752/the-value-of-detection-of-s100a8-and-asah1-in-predicting-the-chemotherapy-response-for-breast-cancer-patients
#8
Yu-Hong Li, Hai-Ting Liu, Jing Xu, Ai-Yan Xing, Jie Zhang, Ya-Wen Wang, Gang Yin, Peng Gao
Chemotherapy plays an important role in the treatment of breast cancer. However, chemoresistance remains the main obstacle for effective treatment, leading to poor prognosis. This study aims to investigate the value of detection of S100A8 and ASAH1 in predicting the chemotherapy response. Miller and Payne grades were used to assess the chemotherapy response in breast cancers. The expression of S100A8 and ASAH1, as well as ER, PR, HER-2 and Ki-67 were assessed by immunohistochemical staining in 120 cases of non-special type invasive ductal carcinoma (IDC-NOS)...
January 7, 2018: Human Pathology
https://www.readbyqxmd.com/read/29318901/ramucirumab-in-her-2-positive-gastroesophageal-adenocarcinoma-an-argument-for-overcoming-trastuzumab-resistance
#9
Mustapha Tehfe, Samer Tabchi, Maria Maddalena Laterza, Ferdinando De Vita
AIM: Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials & methods: We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel...
January 10, 2018: Future Oncology
https://www.readbyqxmd.com/read/29310036/pleomorphic-lcis-what-do-we-know-a-uk-multicenter-audit-of-pleomorphic-lobular-carcinoma-in-situ
#10
Yazan A Masannat, Ehab Husain, Rebecca Roylance, Steven D Heys, Pauline J Carder, Hiam Ali, Yasmine Maurice, Sarah E Pinder, Elinor Sawyer, Abeer M Shaaban
AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans. MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29306240/concordance-of-immunohistochemistry-between-core-needle-biopsy-and-surgical-resection-of-breast-cancer
#11
Faruk Erdem Kombak, Hülya Şahin, Hande Mollamemişoğlu, İdris Önem, Handan Kaya, Onur Buğdaycı, Erkin Arıbal
Background/aim: The purpose of this study was to evaluate the concordance of immunohistochemical (IHC) parameters of breast lesions between the core needle biopsy (CNB) and the surgical resection specimen. Materials and methods: CNB and resection specimens of female patients were retrospectively analyzed. ER, PR, HER-2, and Ki-67 parameters were compared for each patient. A total of 284 cases were assessed. Forty-one and 48 cases were excluded from the HER-2 and Ki-67 examinations, respectively, because the CNBs did not allow for IHC...
December 19, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/29305748/production-of-human-single-chain-fragment-antibody-scfv-against-human-epidermal-growth-factor-receptor-2-her-2-by-phage-display-technology
#12
Saeideh Foroumadi, Masoumeh Rajabibazl, Azam Rahimpour, Solmaz Shahidi, Walead Ebrahimizadeh, Maral Yarahmadi, Shirin Rajabi, Azam Daraei
Breast cancer with more than 1.7 million diagnoses per year has been known as one of the most prevalent cancers among women worldwide. Despite the availability of advanced treatment options, cancer progression and metastasis is observed in 20% of patients. Human epidermal growth factor receptor-2 (HER-2) is considered as an important prognostic and diagnostic tumor marker for breast cancer. While HER-2 is expressed on the surface of normal cells, its overexpression occurs in 20-25% on breast cancer tumor cells...
January 5, 2018: In Vitro Cellular & Developmental Biology. Animal
https://www.readbyqxmd.com/read/29302899/salivary-duct-carcinoma-and-invasive-ductal-carcinoma-of-the-breast-a-comparative-immunohistochemical-study
#13
Jalal B Jalaly, Souzan Sanati, Rebecca D Chernock, Dikson G Dibe, Samir K El-Mofty
Salivary duct carcinoma (SDC) is a high-grade salivary gland malignancy with great morphological resemblance to invasive ductal carcinoma (IDC) of the breast. Rarely, female patients may have a past history of both SDC and IDC. When these patients present with distant metastasis, accurate identification of the primary tumor is particularly difficult. Additionally, rare metastasis of SDC to the breast and IDC to the salivary (parotid) gland can also present a diagnostic challenge. Our aim was to develop an immunohistochemical panel that reliably distinguishes SDC from IDC...
January 4, 2018: Head and Neck Pathology
https://www.readbyqxmd.com/read/29299365/her-2-neu-gene-amplification-in-gastric-adenocarcinoma-and-its-relationship-with-clinical-and-pathological-findings
#14
Ramin Azarhoosh, Rokhsare Ebneghasem, Sima Besharat
Background: Amplification of the HER-2/neu oncogene influences the progression of gastric cancer, its prognosis, and therapy. A precise examination of HER-2/neu-amplified tumor tissue is essential for managing disease and prescribing the appropriate treatment. This study aimed to investigate the status of HER-2/neu gene in the gastric cancer samples and its relationship with clinical and pathological information. Methods: In this study on 80 paraffin-embedded tissue samples from patients with gastric adenocarcinoma [2006-2011], DNA was extracted to quantify the gene expression levels of HER-2 using a polymerase chain reaction (PCR) method...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29291541/her-2-positive-mucinous-carcinoma-breast-cancer-case-report
#15
Irean Garcia Hernandez, Mauricio Canavati Marcos, Margarita Garza Montemayor, Dulce Lopez Sotomayor, Diana Pineda Ochoa, Gabriela Sofia Gomez Macias
INTRODUCTION: Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52-89% for the non-specific carcinoma, it has been described just once in mucinous carcinoma. CASE SUMMARY: A 48-year-old female presented with a lump in her right breast and after a biopsy, it was diagnosed as mucinous carcinoma in the core biopsy and surgical resection, with positive hormone receptors and HER2 positive (3+) in 100% of the tumor cells...
December 26, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29290947/mir-34a-expression-in-human-breast-cancer-is-associated-with-drug-resistance
#16
Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao
miR-34a is significantly down-regulated in breast cancer tissues and cell lines, which may be correlated with breast cancer multi-drug resistance (MDR). Here, we conducted cell-based experiments and clinical studies in a cohort of 113 breast cancer samples to analyze miR-34a expression and breast cancer MDR. Expression of miR-34a is down-regulated in the multi-drug resistant MDR-MCF-7 cells compared with its parental cells. Patients with miR-34a low expression had poorer overall survival (OS) and disease free survival (DFS) in comparison with those with high expression...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29289916/a-novel-missense-mutation-of-the-gtp-cyclohydrolase-1-gene-in-a-taiwanese-family-with-dopa-responsive-dystonia-a-case-report
#17
Chen-Chih Yang, Wei-Chung Wang, Tu-Hsueh Yeh, Tzu-Hsuan Chen, Yen-Liang Liu, Ming-Kuei Lu, Chin-Song Lu, Chon-Haw Tsai
BACKGROUND: Dopa-responsive dystonia (DRD) is a clinical syndrome characterized by early onset dystonia and a dramatic response to relatively low doses of levodopa. The autosomal dominant DRD is caused by mutations in the gene coding GTP cyclohydrolase 1 (GCH1), the enzyme that catalyzes the first step in the biosynthesis of tetrahydrobiopterin. We herein report a novel gene mutation causally links to DRD. SUBJECT AND METHODS: A 23-year-old woman, presented with a history of gait abnormality and leg dystonia at age 15...
December 26, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29286917/protein-and-dna-evidences-of-hcmv-infection-in-primary-breast-cancer-tissues-and-metastatic-sentinel-lymph-nodes
#18
Jian Cui, Qian Wang, Hai-Bo Wang, Bin Wang, Ling Li
BACKGROUND AND OBJECTIVE: Breast cancer is the leading cause of death in women worldwide. There are evidences that human cytomegalovirus (HCMV) infection is associated with several malignant tumors. This study aims to investigate the infection of human cytomegalovirus (HCMV) in a large sample of breast cancer patients, and conduct a correlation analysis of clinical and pathological factors, to provide evidence for whether HCMV infection is associated with breast cancer development, progression and metastasis...
December 19, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29285110/large-scale-ex-vivo-expansion-of-clinical-grade-effector-cells-for-adoptive-immunotherapy
#19
Huiying Yu, Wei Chen, Changling Li, Di Lin, Junde Liu, Zien Yang, Jingang Yang, Yinghui Sun, Dongchu Ma
Cell-based adoptive immunotherapy for the treatment of various cancer types has attracted the attention of scientists. However, due to the absence of unitary standard protocols to produce large quantities of clinical-grade effector cells, it remains challenging to translate the experimental findings into clinical applications. The present study used methods complying with good manufacturing practice to induce effector cells from human peripheral blood mononuclear cells (PBMCs) of healthy donors by interleukin-2 and anti-Her-2 antibody with or without anti-CD3 antibodies (OKT3)...
December 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29282694/immune-checkpoint-blockade-in-breast-cancer-therapy
#20
Xia Bu, Yihui Yao, Xiaoyu Li
Cancer immunotherapy is emerging as the most promising novel strategy for cancer treatment. Cancer immunotherapy is broadly categorized into three forms: immune checkpoint modulation, adoptive cell transfer, and cancer vaccine. Immune checkpoint blockade is demonstrated as the most clinically effective treatment with low immune-related adverse events (irAE). Blockade of PD-1/PD-L1 and CTLA-4 has achieved remarkable success in treating various types of tumors, which sparks great interests in this therapeutic strategy and expands the role of immune checkpoint blockade in treating tumors including breast cancer...
2017: Advances in Experimental Medicine and Biology
keyword
keyword
7437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"